Hospital
Prime Healthcare Services Roxborough LLC
Prime Healthcare Services Roxborough LLC was paid $8.76M by Medicaid between May 2019 and Dec 2024, across 82 billing codes. Its largest line is 99283, emergency room visit (moderate) — 48% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES ROXBOROUGH LLC
PHILADELPHIA, PA 19128
PHILADELPHIA, PA 19128
33aNPI1083986129assigned 02/06/2012
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.76M
24GClaims86,660
24DCodes billed82
24AFirst – last monthMay 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#37 of 154
Median peer was paid$2.82M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 281 | $6K | |
| 2020 | 7,754 | $555K | |
| 2021 | 24,709 | $2.20M | |
| 2022 | 16,606 | $2.10M | |
| 2023 | 16,310 | $2.15M | |
| 2024incomplete | 21,000 | $1.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 48% | 17,621 | 16,690 | $4.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 10,038 | 9,476 | $2.15M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 5,592 | 5,283 | $986K |
| G0378 | Hospital observation service, per hour | 4.9% | 361 | 300 | $428K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.6% | 3,004 | 2,809 | $319K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.0% | 1,974 | 1,794 | $264K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.9% | 714 | 689 | $169K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 1,465 | 1,357 | $123K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 168 | 163 | $36K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 244 | 239 | $20K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 462 | 442 | $8K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 629 | 573 | $7K |
70 more codes
| 80053 | Comprehensive metabolic panel | <1% | 3,245 | $6K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 407 | $5K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,445 | $5K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,668 | $5K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,458 | $5K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 56 | $4K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 108 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 367 | $3K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 469 | $2K |
| 72084 | <1% | 52 | $2K | |
| 84484 | <1% | 1,427 | $2K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 56 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 425 | $2K |
| 73630 | <1% | 262 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,159 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 13 | $1K |
| 81025 | <1% | 2,388 | $1K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 77 | $1K |
| 83880 | <1% | 259 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 875 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,118 | $1K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 496 | $1K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 56 | $990.27 |
| 83690 | <1% | 1,167 | $832.46 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 696 | $742.66 |
| 73030 | <1% | 79 | $667.18 | |
| 81001 | <1% | 1,586 | $610.90 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,089 | $540.18 |
| 85730 | <1% | 449 | $461.80 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 150 | $444.01 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 226 | $437.50 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 265 | $405.38 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 288 | $346.41 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 288 | $346.41 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 65 | $323.67 |
| 73610 | <1% | 56 | $317.44 | |
| 82550 | <1% | 354 | $315.64 | |
| 81003 | <1% | 758 | $305.86 | |
| 85379 | <1% | 145 | $265.00 | |
| 85610 | <1% | 474 | $260.96 | |
| 73562 | <1% | 48 | $228.54 | |
| 83735 | <1% | 240 | $217.50 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 32 | $184.84 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,693 | $176.42 |
| 87186 | <1% | 134 | $175.20 | |
| 83605 | <1% | 218 | $160.00 | |
| 87077 | <1% | 134 | $148.39 | |
| 82962 | <1% | 415 | $117.60 | |
| 84702 | <1% | 38 | $114.94 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,898 | $70.87 |
| J3490 | Unclassified drugs | <1% | 713 | $37.03 |
| 80076 | <1% | 78 | $21.11 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 130 | $17.16 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 30 | $16.42 |
| 85027 | <1% | 15 | $15.04 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 858 | $14.93 |
| A4223 | Infusion supplies not used with external infusion pump, per cassette or bag (list drugs separately) | <1% | 79 | $14.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 13 | $11.08 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 615 | $6.98 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 203 | $6.45 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12 | $6.30 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 378 | $5.31 |
| 87081 | <1% | 30 | $5.20 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 153 | $0.62 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 17 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 76 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 16 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 63 | $0.00 |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | 0% | 16 | $0.00 |
| 87040 | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSARRAO, MICHAEL (VICE-PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Alecto Healthcare Services Fairmont LLC | Fairmont, WV | $11.68M |
| Alecto Healthcare Services Wheeling LLC | Wheeling, WV | $6.00M |
| Alecto Healthcare Services Martins Ferry LLC | Martins Ferry, OH | $963K |
| Alecto Healthcare Services Wheeling LLC | Wheeling, WV | $956K |
| Sherman MD Provider INC | Sherman, TX | $849K |
| FRMC Physicians, INC. | Fairmont, WV | $816K |
| Alecto Healthcare Services Martins Ferry LLC | Martins Ferry, OH | $194K |
| Prime Healthcare Services Pampa LLC | Pampa, TX | $14K |
| Prime Healthcare Services Pampa LLC | Pampa, TX | $7K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.